Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16744704 | 1.00 | MEN1 (0.41) | MEN1KMT2APOLBHTTALDH1A1 | |
| SCHEMBL16744707 | 0.90 | MEN1 (0.34) | MEN1KMT2APOLBHTTALDH1A1 | |
| SCHEMBL16744705 | 0.83 | PTPN2 (0.41) | POLBALDH1A1SMN1; SMN2MAPTALOX5 | |
| SCHEMBL16744731 | 0.80 | PDE4D (0.35) | MEN1KMT2APOLBHTT | |
| SCHEMBL16737859 | 0.76 | PTGDR2 (0.35) | ALDH1A1 | |
| SCHEMBL16737861 | 0.76 | PTGDR2 (0.35) | ALDH1A1 | |
| SCHEMBL16744679 | 0.72 | SRD5A2 (0.35) | MEN1KMT2APOLBHTTALDH1A1 | |
| SCHEMBL16744681 | 0.71 | POLB (0.33) | MEN1KMT2APOLBHTTALDH1A1 | |
| SCHEMBL16744682 | 0.71 | POLB (0.33) | MEN1KMT2APOLBHTTALDH1A1 | |
| SCHEMBL16744703 | 0.70 | HTT (0.46) | MEN1KMT2APOLBHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148313-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | MEN1 1271/4885KMT2A 2571/4885POLB 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.